Tumor necrosis factor receptor-associated factor 1, an adaptor protein of tumor necrosis factor 2, is involved in classical nuclear factor (NF)-κB activation and lymphocyte recruitment. However, less is known about the expression and association of tumor necrosis factor receptor-associated factor 1 with cancer stem cell markers in oral squamous cell carcinoma. This study aimed to investigate the expression of tumor necrosis factor receptor-associated factor 1 and stem cell characteristic markers (lin28 homolog B, B cell-specific Moloney murine leukemia virus integration site 1, and aldehyde dehydrogenase 1) in oral squamous cell carcinoma and analyze their relations. Paraffin-embedded tissues of 78 oral squamous cell carcinomas, 39 normal oral mucosa, and 12 oral dysplasia tissues were employed in tissue microarrays, and the expression of tumor necrosis factor receptor-associated factor 1, B cell-specific Moloney murine leukemia virus integration site 1, aldehyde dehydrogenase 1, and lin28 homolog B was measured by immunohistostaining and digital pathological analysis. The expression of tumor necrosis factor receptor-associated factor 1 was higher in the oral squamous cell carcinoma group as compared with the expression in the oral mucosa (p < 0.01) and oral dysplasia (p < 0.001) groups. In addition, the expression of tumor necrosis factor receptor-associated factor 1 was associated with those of B cell-specific Moloney murine leukemia virus integration site 1, aldehyde dehydrogenase 1, and lin28 homolog B (p = 0.032, r 2 = 0.109; p < 0.0001, r 2 = 0.64; and p < 0.001, r 2 = 0.16) in oral squamous cell carcinoma. The patient survival rate was lower in the highly expressed tumor necrosis factor receptor-associated factor 1 group, although the difference was not significant. The clustering analysis showed that tumor necrosis factor receptor-associated factor 1 was most related to aldehyde dehydrogenase 1. These findings suggest that tumor necrosis factor receptor-associated factor 1 has potential direct/indirect regulations with the cancer stem cell markers in oral squamous cell carcinoma, which may help in further analysis of the cancer stem cell characteristics.
Introduction
Oral squamous cell carcinoma (OSCC) is a common malignant tumor of the head and neck. In the last 50 years, its clinical survival rate is less than 50% even after treating with systematic combined therapy, including surgery, chemotherapy, and radiotherapy. 1, 2 Hence, the molecular factors that play important roles in OSCC carcinogenesis, progression, and targeted therapy need to be identified. mutation play important roles in cancer development and cancer cell origin. 3 Tumor necrosis factor receptor-associated factors (TRAFs) are adapter proteins that connect several signaling pathways and are involved in nuclear factor (NF)-κB and interferon regulatory factor (IRF) signaling activation. TRAF1 is different from six other TRAFs. It has no ring structure and no rearranged zinc finger area. 4 By interacting with downstream signaling molecules, TRAFs are involved in the activation of NF-κB signaling. TRAF1 expression is upregulated in nasopharyngeal carcinoma and Hodgkin's lymphoma. 5, 6 However, the expression of TRAF1 in OSCC remains to be determined.
Lin28 homolog B (Lin28B) is an RNA-binding protein and a paralog of Lin28A in human species. When combined with Nanog, Oct4, and Sox2, Lin28B can induce human somatic cells into pluripotent cells; when combined with let-7 signaling, Lin28B plays an important role in the regulation of key cancer stem-like properties in OSCC. [7] [8] [9] Lin28B expression is upregulated in OSCC, which can promote oral cancer cell migration, invasion, colony formation, epithelial-mesenchymal transition (EMT), and in vivo proliferation. 10 B cell-specific Moloney murine leukemia virus integration site 1 (BMI-1), a key component of the PcG family, participates in DNA repair, chromosome reconstruction, gene translation, and cell apoptosis. BMI-1 is highly expressed in several primary malignant types of cancer and lowly expressed in normal tissues; 11 in specific, BMI-1 is highly expressed in OSCC and predicts poor progression and clinical outcome. 12, 13 Aldehyde dehydrogenase 1 (ALDH1), a member of the ALDH family, can catalyze the conversion of acetaldehyde to acetic acid and is highly expressed in cancer stem cells. [14] [15] [16] Current studies have shown that ALDH1 is a cancer stem cell marker in lung, pancreatic, prostate, and head and neck cancers. 17 To date, no study has performed a comprehensive analysis of the expression of TRAF1 in human OSCC and its associations with Lin28B, BMI-1, and ALDH1 expression in OSCC and patients' clinical outcome. In this study, we examined the expression of TRAF1 in OSCC and its associations with Lin28B, ALDH1, and BMI-1 in OSCC by employing tissue microarrays. We also analyzed their roles in the prognosis of OSCC through relevance analysis between pathologic features and clinical outcome.
Methods and materials

Ethics statement
This study was approved by the Ethics Committee of the School and Hospital of Stomatology, Wuhan University, and all specimens were processed in accordance with the World Medical Association Declaration of Helsinki (Version 2008) and with the National Institutes of Health Guidelines regarding the use of human tissues. Each individual in this study had signed and approved the informed consent before surgery.
Patient samples
We determined the expression of TRAF1, Lin28B, ALDH1, and BMI-1 in primary surgically resected oral cancer tissues from the Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, from January 2008 to August 2010. These tissue samples were formalin-fixed, paraffin-embedded, and archived. All cases were diagnosed and confirmed for OSCC by pathological examination after surgery. The clinical stages of OSCC were classified in accordance with the guidelines of the Union for International Cancer Control (UICC, 2002). 18 The pathological grade, tumor, node, metastasis (TNM) stage, and the survival data are presented in Table 1 .
Tissue microarrays
Custom-made tissue microarrays (T12-412 TMA and T12-412 TMA2) were constructed by selecting OSCC specimens from above paraffin-embedded tissues, including 78 OSCCs (eluted tissue dots were excluded), 39 normal tissues, and 12 dysplastic tissues. Clinicopathologic information, including T category, lymph node metastasis, TNM stage, histological grade, and follow-up information was available for all specimens.
Immunohistochemical staining
Immunohistochemistry was performed using the streptavidin-peroxidase method. 19, 20 Immunohistochemical studies for tissue arrays were performed using the following antibodies: Lin28B (1:200) from Proteintech (Chicago, USA) and Rabbit anti-Human Polyclonal TRAF1 (1:100), Rabbit anti-Human Polyclonal BMI-1 (1:800), and Rabbit anti-Human Polyclonal ALDH1 (1:800) from GeneTex (Irvine, USA). Before using the gradient concentration, it was first tested in paraffin tissue sections. Detailed tissue-section procedures, including antigen retrieval, primary antibody conjugation, secondary antibody conjugation, and immunostaining visualization, were conducted as previously described. 10 In brief, the tissue sections were deparaffinized, hydrated, antigen retrieved, conjugated with primary and then secondary antibodies, and finally visualized by diaminobenzidine and hematoxylin.
Staining assessment
As described earlier, high-resolution tissue array staining images were automatically scanned by the Aperio ScanScope CS scanner (Vista, CA, USA). 21 The staining spots for TRAF1, Lin28B, ALDH1, and BMI-1 were outlined and then analyzed using Aperio Quantification software (Vista, CA, USA) (Version 9.1). Then, the staining intensities of the Table 1 . Clinicopathological characteristics of HNSCC used in this study.
Case
Grade TNM Alive or dead Survival time (months)   1  I  T2N0M0  Dead  10  2  I  T1N1M0  Alive  42  3  I  T1N1M0  Alive  45  4  I  T2N0M0  Alive  48  5  I  T2N0M0  Alive  50  6  I  T1N0M0  Alive  56  7  I  T2N1M0  Alive  55  8  I  T1N0M0  Alive  48  9  I  T2N0M0  Alive  39  10  I  T2N1M0  Alive  37  11  I  T3N0M0  Alive  36  12  I  T1N0M0  Dead  6  13  I  T2N0M0  Alive  34  14  I  T1N0M0  Alive  34  15  II  T2N0M0  Alive  44  16  II  T3N1M0  Dead  9  17  II  T3N0M0  Dead  12  18  II  T2N1M0  Dead  18  19  II  T1N0M0  Alive  56  20  II  T3N0M0  Alive  51  21  II  T3N0M0  Alive  53  22  II  T2N0M0  Alive  51  23  II  T2N1M0  Dead  6  24  II  T1N1M0  Alive  48  25  II  T2N1M0  Alive  65  26  II  T2N1M0  Dead  8  27  II  T2N0M0  Alive  37  28  II  T3N0M0  Alive  48  29  II  T2N1M0  Alive  42  30  II  T2N1M0  Dead  17  31  II  T2N1M0  Dead  10  32  II  T2N0M0  Dead  7  33  II  T2N0M0  Alive  53  34  II  T2N0M0  Alive  54  35  II  T3N1M0  Dead  30  36  II  T2N0M0  Dead  16  37  II  T2N1M0  Dead  17  38  II  T2N0M0  Dead  7  39  II  T2N0M0  Dead  7  40  II  T3N1M0  Alive  18  41  II  T2N1M0  Dead  27  42  II  T3N1M0  Alive  32  43  II  T3N0M0  Alive  35  44  II  T2N0M0  Alive  34  45  II  T1N0M0  Dead  3  46  II  T1N0M0  Alive  34  47  II  T2N1M0  Alive  33  48  II  T2N2M0  Dead  19  49  II  T2N0M0  Dead  18  50  II  T2N0M0  Alive  33  51  II  T2N0M0  Alive  33  52  II  T1N0M0  Alive  32  53  II  T2N0M0 Alive 32 (Continued) nucleus and membrane were calculated as previously described. 19 With these methods, each tissue spot and staining was scored. Finally, we used the scores for subsequent analysis. Using the median score values of TRAF1, the expression was divided into TRAF1-high and TRAF1-low groups, and this cutoff method was also used in the group division for Lin28B, ALDH1, and BMI-1. 10, 19, 21 Hierarchical clustering
The staining scores were converted into the database (Organized Notepad pattern) that Cluster 3.0 needed, and then the data were adjusted in Cluster 3.0 by log transformation and generated scaled value data. 22 
Statistical analysis
Most of the statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, USA) (Version 5.01). One-way analysis of variance (ANOVA), followed by the Tukey test, was used for group difference comparison; log-rank test was used for survival rate difference; and linear regression analysis was used for expression level associations. Clustering analysis was used for the protein expression scattering and associations. Statistical significance was considered at p < 0.05.
Results
Increased expression of TRAF1, ALDH1, BMI-1, and Lin28B in OSCC
TRAF1 was mainly expressed in the cell cytoplasm in OSCC; its expression was significantly higher in OSCC (n = 78) specimens than in normal oral mucosa (OM; Figure 1 (a), (b), and (i); n = 39, p < 0.01) and in the dysplasia tissues (p < 0.001). However, the difference between the mucosa and dysplasia tissues was not significant (Figure 1(i) ). BMI-1 was mainly expressed in the cell nucleus; its expression was similar in the normal mucosal, dysplastic, and OSCC groups (Figure 1(c) , (d), and (j)). ALDH1 was mainly expressed in the cytoplasm; its expression was significantly higher in OSCC and dysplasia tissues (Figure 1(e ), (f), and (k); p < 0.001) than in normal OM tissues (Figure 1(k) ). Lin28B was mainly expressed in the cytoplasm; its expression was higher in OSCC tissues than in dysplasia and normal tissues (Figure 1(g) , (h), and (l); p < 0.05). Grade  TNM  Alive or dead  Survival time (months)   54  II  T3N0M0  Dead  21  55  II  T2N1M0  Dead  29  56  II  T2N0M0  Alive  34  57  II  T2N0M0  Dead  23  58  II  T1N0M0  Alive  34  59  II  T2N1M0  Alive  34  60  II  T2N0M0  Dead  9  61  II  T2N0M0  Dead  14  62  II  T2N0M0  Alive  33  63  II  T2N1M0  Alive  36  64  II  T2N0M0  Alive  34  65  II  T1N0M0  Dead  34  66  II  T2N0M0  Dead  22  67  II  T2N0M0  Alive  34  68  II  T2N1M0  Alive  10  69  II  T2N1M0  Alive  35  70  II  T3N1M0  Alive  36  71  III  T3N0M0  Alive  35  72  III  T2N1M0  Alive  34  73  III  T2N1M0  Alive  33  74  III  T2N0M0  Alive  33  75  III  T2N0M0  Alive  33  76  III  T2N0M0  Dead  12  77  III  T1N0M0  Alive  35  78  III  T2N1M0  Dead  6 HNSCC: head and neck squamous cell carcinoma; TNM: tumor, node, metastasis. 
Case
Expression of TRAF1, BMI-1, ALDH1, and Lin28B in OSCC analyzed by pathological grades and TNM stages
Considering that different pathological grades are often associated with different clinical outcomes, we examined the expression levels of TRAF1, BMI-1, ALDH1, and Lin28B in pathological grade I, II, and III. TRAF1 expression was similar in the three groups (Figure 2(a) ). BMI-1 expression was significantly higher in the high-grade group than in the clinical-grade II group (Figure 2(b) ; p < 0.01), but it was higher in the grade I group than in the grade-II group (Figure 2(b) ; p < 0.001). Meanwhile, the difference in BMI-1 expression between grade I and III groups was not significant. ALDH1 expression was similar in the three pathological groups (Figure 2(c) ). Lin28 expression level was higher in grade III than in grades I and II, the difference was not significant (Figure 2(d) ). Different clinical stages were also involved in the patients' final outcome. In accordance with the guidelines of American Joint Committee on Cancer (2010, 7th edition), we divided the samples into I-II and III-IV groups, and then compared their difference in protein expression levels. Interestingly, TRAF1 expression was similar in the two clinical-stage groups (Figure 2(e) ; p = 0.08). BMI-1 expression was lower in the III+IV group (Figure 2(f) ; p = 0.21), while ALDH1 (Figure 2(g) ; p = 0.31) and Lin28B (Figure 2(h) ; p = 0.47) expression levels were similar in both groups.
Survival curves of TRAF1, BMI-1, ALDH1, and Lin28B in OSCC
The expression of TRAF1 was divided into TRAF1-low and TRAF1-high groups by the median expression levels on the basis of the method used in our previous work. 10, 19, 21 This group sorting method was also used for the expression of BMI-1, ALDH1, and Lin28B. We found through the Kaplan-Meier analysis that patients with high TRAF1 expression had worse overall survival rates, but the difference was not significant (Figure 3(a) ; p = 0.42). The same findings were obtained in the expression of BMI-1 (Figure 3(b) ) and Lin28 (Figure 3(d) ) in oral cancer tissues (p = 0.56 and p = 0.6, respectively). The higher expression levels of ALDH1 did not indicate a worse overall survival rate than the lower expression group (Figure 3(c) ).
Associations of TRAF1, Lin28B, BMI-1, and ALDH1 in OSCC
We also analyzed the associations of TRAF1, Lin28B, BMI-1, and ALDH1 proteins in OSCC by Pearson's correlation coefficient test. Results showed that TRAF1 was Figure 2. (a, b, c, and d) The top row showed expression levels for TRAF1, BMI-1, ALDH1, and Lin28B in pathological groups (grade I, II, and III). (e, f, g, and h) The lower row showed expression levels for TRAF1, BMI-1, ALDH1, and Lin28B in clinical groups (I-II stage, III-IV stage). associated with BMI-1 (Figure 4(a) ; p < 0.05, r 2 = 0.109), ALDH1 (Figure 4(b) ; p < 0.0001, r 2 = 0.64), and Lin28B (Figure 4(c) ; p < 0.001, r 2 = 0.16); BMI-1 was associated with ALDH1 ( Figure 4(d) ; p < 0.0001, r 2 = 0.30) and Lin28B (Figure 4(e) ; p < 0.01, r 2 = 0.09); and ALDH1 was associated with Lin28B ( Figure 4(f) ; p < 0.001, r 2 = 0.26). However, though the p values were less than 0.05, only the r 2 of TRAF1 and ALDH1 was greater than 0.5 and closer to 1. Hence, we performed the hierarchical clustering of TRAF1, Lin28B, BMI-1, and ALDH1, which showed similar result that TRAF1 was most related to ALDH1. (Figure 4(g) ).
Discussion
Chronic inflammation is common in patients with oral cancer. 24 The accumulated reactive oxygen species and nitrogen intermediates that are produced by inflammatory cells can damage cell DNA and increase cell malignancy. 25 The cytokines and enzymes (epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), matrix protease, cysteine cathepsin, and heparanase) produced by inflammatory cells can promote cancer development. In addition, activated NF-κB can invoke Wnt signaling and, hence, promote cell dedifferentiation, which improves the stem cell characteristics for malignant cells. 26 Although the exact relation between inflammation and cancer cell origin is unclear, a possibility of inflammation-induced cancer stem cell exists. 27 In this study, we found TRAF1, an upstream molecular factor of NF-κB associated with the cancer stem cell marker of BMI-1, ALDH1, and Lin28B in oral cancer may have a potential relation in their molecular mechanism functions. TRAF1 was originally discovered in 1994, 28 and the human homolog type was found a year later. 29 Since then, it has been established that TRAF1 is a unique type of TRAF because it lacks the ring domain in the N-terminal regions and possesses multiple functions in cytokine signaling. The promoter area of TRAF1 reportedly contains several binding sites that can be activated by NF-κΒ, as found by electrophoretic mobility shift assay studies and luciferase functional analyses. Importantly, NF-κB activation can also upregulate TRAF1. 30 TRAF1 can also inhibit tumor necrosis factor (TNF)-α-induced cell apoptosis by binding to the TNFR1-TNFR-associated death domain protein (TRADD) complex. 5, 6, 31 TRAF2 and TRAF5 are similar in structure and function, and participate in NF-κβ, mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinase (JNK) signaling activation. TRAF3 could not activate the JNK or NF-κB pathways. TRAF4 over-expression or deletion in animal models does not result in tumor development. TRAF6 deficiency can lead to the abnormal formation of skin appendices and development of the nervous system. 32 Emerging data indicate that the NF-κB-related inflammation state in local tissues is associated with stem celllike properties in carcinogenesis. 33 Stem cell markers, including BMI-1, ALDH1, and Lin28B, are associated with head and neck tumorigenesis. 6, 7, 17 About 40.9% of oral leukoplakia patients with BMI-1 positivity develop oral cancer. 12 ALDH1-high cancer cells exhibit a high tumor sphere-forming ability. 17 The reprogramming factor Lin28B promotes cancer stem-like properties in oral cancer. 7 Inflammation site cytokines, such as transforming growth factor (TGF)-β, leukemia inhibitory factor, (LIF), basic fibroblast growth factor (b-FGF), and interleukin (IL)-6, can directly or indirectly upregulate the stem cell marker characteristics, including Lin28, Sox2, Nanog, and Oct4. 10, 34 Hence, we analyzed the association of ALDH1, Lin28, and BMI-1 expression with the expression of the NF-κB upstream regulator TRFA1 in oral cancer tissues.
In this study, high expression levels of TRAF1, ALDH1, and Lin28B were observed in oral cancer, but the difference in expression of each protein was not significant between the clinical stages and pathological stages. Considering that the samples were dotted and stained in the same supporter and collected by a digital scanner in tissue arrays, we speculated that no significant association exists with the patients' pathological information. We also found that high expression levels of TRAF1 were associated with the patients' poor prognosis, but the association was not significant (p = 0.42), which was also found in the Lin28B (p = 0.6) and BMI-1 (p = 0.56). Absence of such significant differences might be due to the small quantity in this batch of samples or due to the variations, such as sample sites, visual field of statistics (for field, dot in tissue array is less than the traditional section), and follow-up time. Hence, the statistical result of the prognosis value of TRAF1, BMI-1, ALDH1, and Lin28B in OSCC in this study needs to be further integrated and analyzed with other sample database and by molecular mechanism studies. Interestingly, the expression of TRAF1 showed a significant association with the expression of Lin28B (p < 0.001), BMI-1 (p = 0.032), and ALDH1 (p < 0.0001) in oral cancer tissues. This association was also found in the expression level clustering (Figure 4 ). Our early study and other groups had reported that Lin28B can promote cell malignancy, 10, 35 cancer progression, and inflammation-induced carcinogenesis, 33 BMI-1 with oral carcinogenesis, 13 and ALDH1+ cells show cancer stem cell characteristics. 14, 15, 17 Considering the above mentioned points, we speculated potential relation of TRAF1 with stem cell subpopulations in oral cancer, which needs to be investigated further by molecular mechanism studies.
In conclusion, TRAF1 is highly expressed in OSCC tissues and associated with cancer stem cell markers of ALDH1, Lin28, and BMI-1. TRAF1 as a NF-κB upstream regulator may be involved in inflammation-induced cancer stem cell characteristics.
